-
Mashup Score: 20Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial - 3 month(s) ago
This article reports an analysis of clinical outcomes using predicted modeling of circulating tumor cells to stratify stage IV disease. Results suggest the need
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Metastatic Breast Cancer Support and Education - Dana-Farber Cancer Institute | Boston, MA - 6 month(s) ago
One of the goals of the Ending Metastatic Breast Cancer for Everyone (EMBRACE) program is to provide resources and information to help guide patients through many situations and decisions. Throughout their journey, metastatic breast cancer patients in the EMBRACE program receive education and support from expert clinicians, other professionals, and one another.
Source: www.dana-farber.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Suzanne Somers died on Oct. 15 at 76. The actress was best known for her roles on ‘Three’s Company’ and ‘Step by Step.’
Source: PEOPLE.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6Metastatic Breast Cancer Support and Education - Dana-Farber Cancer Institute | Boston, MA - 6 month(s) ago
One of the goals of the Ending Metastatic Breast Cancer for Everyone (EMBRACE) program is to provide resources and information to help guide patients through many situations and decisions. Throughout their journey, metastatic breast cancer patients in the EMBRACE program receive education and support from expert clinicians, other professionals, and one another.
Source: www.dana-farber.orgCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 0Physicians Discuss Elacestrant Vs Alternatives in ER+, HER2- MBC - 6 month(s) ago
During a Targeted Oncology™ Case-Based Roundtable™ event, Reshma L. Mahtani, DO, discussed with other physicians their experience with elacestrant in patients with estrogen receptor–positive, HER2-negative breast cancer. This is the second article based on this event.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Background although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations are simplistically dichotomized as mutated or wild type in current clinical practice. Methods The study analyzed a multi-institutional cohort comprising 703 patients with luminal-like MBC characterized for circulating tumor DNA through next generation sequencing (NGS). Pathway classification was defined based on previous work (i.e., RTK, RAS, RAF, MEK, NRF2, ER, WNT, MYC, P53, cell cycle, notch, PI3K). Single nucleotide variations (SNVs) were annotated for their oncogenicity through OncoKB. Only pathogenic variants were included in the models. Associations among clinical characteristics, pathway classification, and ESR1/PIK3CA codon variants were explored. Results The results showed a differential pattern of associations for ESR1 and PIK3CA codon variants in terms of co-occurring pathway alterations patterns of metastat
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 40Expanding Global Impact Through Collaboration to Improve Breast - 7 month(s) ago
The “Improving Metastatic Breast Cancer (mBC) Patient Quality of Care and Equity in Latin America” grant will support nine projects in seven countries throughout Latin America and the Caribbean.
Source: connection.asco.orgCategories: Latest Headlines, Partners & KOLsTweet-
On #WorldCancerResearchDay, we’re excited to announce our new grant, Improving #mBC Patient Quality of Care & Equity in Latin America, which supports 9 projects in 7 countries that use novel approaches to addressing inequities. https://t.co/vFdjJbNsBK @jrgralow @ConquerCancerFd https://t.co/k5gPjrwYqu
-
-
Mashup Score: 16CTG Labs - NCBI - 8 month(s) ago
Hide glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.
Source: clinicaltrials.govCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 5U.S. Announces First Drugs Picked for Medicare Price Negotiations - 8 month(s) ago
The Biden administration’s announcement was an important moment for Democrats, who have campaigned on a promise to lower the cost of prescription drugs.
Source: www.nytimes.comCategories: Latest Headlines, Oncologists1Tweet-
Happy for the #InflationReductionAct & its promise to lower the cost of Rx drugs for those on Medicare... BUT I was really hoping for Ibrance/Palbociclib on this list to improve access & reduce #financialToxicity for our pts w #mBC #BreastCancer #bcsm💊🫥 https://t.co/571ERnPmQ1 https://t.co/qcgaY37JsL
-
-
Mashup Score: 0Tucatinib/Letrozole/Palbociclib Combo Shows Initial Efficacy in HR+/HER2+ Metastatic Breast Cancer - 8 month(s) ago
At median follow up of 33.6 months, patients who received the triplet combination of tucatinib, letrozole, and palbociclib, experienced a median progression-free survival of 8.4 months.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial https://t.co/QAkeFX9xT4 @CtcLaboratory @WCMEnglanderIPM @WCMEnglanderIPM #MBC